Physician profile
David M Lawrence
NPI 1083698088
$14,895.11
in general payments reported to CMS, 2019-2025
27 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,538 · 2020: $130 · 2021: $4,027 · 2022: $736 · 2023: $618 · 2024: $1,132 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548 · Travel and Lodging: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.44 |
| Travel and Lodging | $916.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $6,238.58 | 2019 | |
| Medtronic, INC. | $4,396.79 | 2021-2025 | Hawkone, Concertotm, In.Pact Admiral |
| Bolton Medical INC | $1,318.37 | 2021-2025 | Treo Abdominal Stent-Graft System, Relay Thoracic Stent-Graft With Plus Delivery System |
| W. L. Gore & Associates, INC. | $508.98 | 2019-2022 | |
| Silk Road Medical, INC. | $419.31 | 2020-2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Lemaitre Vascular, INC. | $304.50 | 2021-2025 | Artegraft Vascular Graft, Hydro Lemaitre Valvulotome |
| Abbott Laboratories | $302.60 | 2019-2023 | Jeti Peripheral Catheter, Jeti |
| Angiodynamics, INC. | $214.66 | 2020-2025 | Auryon Laser System 100-120 Vac |
| Janssen Pharmaceuticals, INC | $176.00 | 2021-2023 | Xarelto |
| Terumo Medical Corporation | $149.32 | 2023 | Azur Cx Detachable |
| Shockwave Medical, INC | $109.70 | 2021 | |
| Artivion, INC. | $101.41 | 2023 | Vascular, On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder |
| Penumbra, INC. | $96.50 | 2022-2025 | Penumbra System |
| Bard Peripheral Vascular, INC. | $93.79 | 2019-2021 | |
| Stryker Corporation | $81.82 | 2025 | Artix Mt, Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $79.71 | 2021-2024 | Eluvia |
| Endologix LLC | $68.08 | 2019 | |
| Cardiovascular Systems INC. | $45.40 | 2021 | |
| Philips North America LLC | $32.60 | 2021 | |
| Inari Medical, INC. | $31.19 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Biocompatibles, INC. | $21.69 | 2019 | |
| Cook Medical LLC | $19.29 | 2024 | Rosen |
| Convatec INC. | $18.72 | 2023 | |
| Admedus Corporation | $17.63 | 2019 | |
| Surmodics, INC. | $16.38 | 2023 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Microcatheter, 014, 65cm, Straight, Sublime Microcatheter, 014, 65cm, Angle |
| Merck Sharp & Dohme LLC | $16.37 | 2025 | Bridion |
| Medela LLC | $15.72 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.